Yan Leyfman, MD

Dr. Yan Leyfman has been recognized as one of the top international researchers in oncology by the American Society of Hematology and American Society of Clinical Oncology (ASCO). He has contributed to the development of several anti-cancer therapies that have recently entered clinical trials and new treatment recommendations of care. His successes have been recognized by the Goldwater Research Foundation, Sigma Xi, New York Times, and Harvard Medical School. During the COVID-19 pandemic, he was recruited to join the Global COVID-19 Taskforce to serve as Director of the Immunology Division, which produced one of the first mechanisms for SARS-CoV-2 and COVI-Flu along with therapeutic interventions for both. In June 2021, Dr. Leyfman presented the first mechanism to explain the interplay between cancer and COVID-19 at the 2021 ASCO Annual Meeting, which was recently published in BMC’s Journal of Hematology & Oncology. His work has been published as the cover article in the journal, Shock, and in the textbook, Insights on a Post-COVID World. Over the past year, Yan was recognized as the 2020 iCHEM Emerging International Scholar in Immunology & Immunotherapy, 2020 New York State & City Manhattan Hero for his community service and research contributions during the COVID-19 pandemic and by Memorial Sloan Kettering Cancer Center for research excellence. Dr. Leyfman was recognized as a 2021 & 2022 Hero in Healthcare for research contributions to cancer & COVID-19 at the Lymphoma, Leukemia & Myeloma Congress and amongst the top 6 early career scientists for 2022 in recognition of his contributions to cell and immunotherapy with a 2023 Phacilitate Advanced Therapies Young Scientist Award.

Got a question for Yan Leyfman, MD?

Get in touch using the contact form linked here and we’ll get back to you shortly